erythromycin-estolate and Respiratory-Tract-Infections

erythromycin-estolate has been researched along with Respiratory-Tract-Infections* in 4 studies

Other Studies

4 other study(ies) available for erythromycin-estolate and Respiratory-Tract-Infections

ArticleYear
Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Digestive diseases and sciences, 1982, Volume: 27, Issue:8

    Two patients experienced hepatotoxicity associated with erythromycin estolate (Ilosone) usage, followed 13 and 15 years later by an hepatotoxic reaction with administration of erythromycin ethylsuccinate (E.E.S.). These cases provide further evidence for erythromycin ethylsuccinate-associated hepatotoxicity and demonstrate erythromycin cross-sensitivity after previous erythromycin estolate liver injury. Hepatotoxicity to both sensitivity after previous erythromycin estolate liver injury. Hepatotoxicity to both estolate and ethylsuccinate preparations of erythromycin stimulates speculation regarding the potentially hepatotoxic moiety of the erythromycin molecule. Furthermore, these cases suggest that all erythromycin preparations should be avoided or used only with careful monitoring in patients with previous erythromycin-associated liver injury.

    Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Dermatitis; Erythromycin; Erythromycin Estolate; Erythromycin Ethylsuccinate; Female; Humans; Liver; Male; Respiratory Tract Infections

1982
Cefadroxil monohydrate versus erythromycin in paediatric patients.
    The Journal of international medical research, 1981, Volume: 9, Issue:2

    Cefadroxil monohydrate, an oral cephalosporin with a long half-life, was compared to erythromycin estolate for efficacy in treating upper respiratory tract infections in children. The study was carried out on forty patients, twenty receiving cefadroxil and twenty receiving erythromycin. Each drug was dosed at 50 mg/kg/day and was given every 12 hours in two equally divided doses. The complete cure rate was 95% for the cefadroxil group and 80% for the erythromycin group. Two patients originally in the erythromycin test group showed no improvement either bacteriologically or clinically after 3 days of treatment. It was found that these patients harboured S. aureus which had become resistant to erythromycin during the course of therapy. Both patients were shifted to cefadroxil treatment and achieved complete cures. Two patients in the erythromycin group and one in the cefadroxil group were diagnosed as having scarlet fever. All three responded clinically, yet cultures from the two treated with erythromycin showed persistence of bacteria while the one treated with cefadroxil proved to be cured both clinically and bacteriologically.

    Topics: Cefadroxil; Cephalexin; Child; Child, Preschool; Erythromycin; Erythromycin Estolate; Female; Humans; Infant; Male; Otitis Externa; Otitis Media; Respiratory Tract Infections

1981
Treatment of acute bacterial infections of the upper respiratory tract.
    Current medical research and opinion, 1977, Volume: 4, Issue:8

    An open comparative study was carried out to assess the effectiveness of 4 antibiotic regimens in eradicating acute bacterial infections of the upper respiratory tract. Patients in each treatment group had similar physical parameters, severity of disease and bacterial pathogens, and were treated for 10 days with either erythromycin estolate, erythromycin stearate, ampicillin or oxytetracycline in the recommended dosage. Each patient was reviewed daily by physical examination and the bacteriological findings from throat swab and salivary washings. The results showed that erythromycin stearate produced more rapid bacterial eradication and clinical resolution of symptoms and fever than with the other antibiotic preparations, and was well tolerated by most patients.

    Topics: Acute Disease; Ampicillin; Bacterial Infections; Erythromycin; Erythromycin Estolate; Escherichia coli Infections; Humans; Oxytetracycline; Penicillin Resistance; Respiratory Tract Infections; Stearates

1977
Comparison of erythromycin ethyl succinate, stearate and estolate treatments of group A streptococcal infections of the upper respiratory tract.
    Clinical pediatrics, 1975, Volume: 14, Issue:12

    The microbiologic and clinical responses of acute Group A beta-hemolytic streptococcal infections of the upper respiratory tract to oral treatment with erythromycin ethyl succinate, stearate, and estolate were studied in 303 patients. Streptococcal M and T typing was done on all positive cultures. The overall cure rate was 95.4 per cent, with no statistically significant differences in clearing organisms from the pharynx. Of the 285 cured patients who completed the prescribed follow-up period, 11 had recurrences between the 12th and 31st day after initiation of therapy, and five developed new infections. No cases of rheumatic fever or glomerulonephritis were encountered during a follow-up study. Eight gastrointestinal reactions and one transient rash occurred. Results with these forms of erythromycin compare favorably with published results for similar infections treated with oral penicillins.

    Topics: Administration, Oral; Child; Child, Preschool; Erythromycin; Erythromycin Estolate; Female; Follow-Up Studies; Humans; Infant; Male; Penicillins; Recurrence; Respiratory Tract Infections; Stearates; Streptococcal Infections; Streptococcus pyogenes; Succinates

1975